Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System

Journal of Clinical Pharmacy and Therapeutics

Volumn 41, Issue 6, 2016, Pages 718-721

  Flaig, T ^a   Douros, A ^a   Bronder, E ^a   Klimpel, A ^a   Kreutz, R ^a   Garbe, E ^b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

Author keywords

acute pancreatitis; adverse event; drug safety; drug induced pancreatitis; pharmacovigilance; RoActemra; tocilizumab

Indexed keywords

TOCILIZUMAB; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; MEDICAL HISTORY; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; CHEMICALLY INDUCED; PANCREATITIS; UNITED STATES;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MALE; PANCREATITIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84992456209     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12456     Document Type: Article

References (33)

1. Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. Curr Gastroenterol Rep, 2012;14:131–138.
2. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf, 2008;31:823–837.
3. Vinklerova I, Prochazka M, Prochazka V, Urbanek K. Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci, 2010;55:2977–2981.
4. Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther, 2003;17:887–893.
5. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case–control study. Am J Gastroenterol, 2003;98:1305–1308.
6. Lantarel full prescribing information [Internet]. Available at: http://fachinfo.de/pdf/004477#view=FitH&pagemode=none&toolbar=1&statusbar=0&messages=0&navpanes=0 (accessed 13 February 2015).
7. Takeuchi T, Tanaka Y, Amano K et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients – REACTION 52-week study. Rheumatology (Oxford, England), 2011;50:1908–1915.
8. Alfreijat M, Habibi M, Bhatia P, Bhatia A. Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford, England), 2013;52:1340–1341.
9. Parekh PJ, Howerton D, Johnson DA. Not your everyday case of acute pancreatitis: a rare complication of a common diagnosis. ACG Case Rep J, 2013;1:40–43.
10. Committee for Medicinal Products for Human Use (CHMP). RoActemra (Tocilizumab) – Summary of Opinion [Internet]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000955/WC500170068.pdf (accessed 2 September 2014).
11. Roche. Ro Actemra full prescribing information [Internet]. Available at: http://fachinfo.de/pdf/011650#view=FitH&pagemode=none&toolbar=1&statusbar=0&messages=0&navpanes=0 (accessed 23 June 2014)
12. Fricke U, Schwabe U. Neue Arzneimittel 2009. In: Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2010 [medicine prescribing report 2010]. Heidelberg: Springer-Verlag, 47–126, 2010.
13. Böger R, Schwabe U. Antirheumatika und Antiphlogistika. In: Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2011 [medicine prescribing report 2011]. Heidelberg: Springer-Verlag, 441–461, 2011.
14. Böger R, Schwabe U. Antirheumatika und Antiphlogistika. In: Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2012 [medicine prescribing report 2012]. Heidelberg: Springer-Verlag, 447–467, 2012.
15. Schwabe U. Arzneiverordnungen 2012 im Überblick. In: Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2013 [medicine prescribing report]. Heidelberg: Springer-Verlag, 3–46, 2013.
16. Actemra Approval History [Internet]. Available at: http://www.drugs.com/history/actemra.html (accessed 12 July 2014).
17. Garbe E, Andersohn F, Bronder E et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol, 2012;68:821–832.
18. Douros A, Bronder E, Andersohn F et al. Drug-induced acute pancreatitis: results from the hospital-based Berlin case–control surveillance study of 102 cases. Aliment Pharmacol Ther, 2013;38:825–834.
19. Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H et al. Drug induced immune haemolytic anaemia in the Berlin Case–Control Surveillance Study. Br J Haematol, 2011;154:644–653.
20. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol, 2006;101:2379–2400.
21. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol, 2002;97:1309–1318.
22. Frank B, Gottlieb K. Amylase normal, lipase elevated: is it pancreatitis? A case series and review of the literature. Am J Gastroenterol, 1999;94:463–469.
23. Ratiopharm GmbH. Ramipril full prescribing information [Internet]. Available at: http://fachinfo.de/pdf/008227#view=FitH&pagemode=none&toolbar=1&statusbar=0&messages=0&navpanes=0 (accessed 4 February 2015).
24. WHO-UMC.The use of the WHO-UMC system for standardised case causality assessment [Internet]. Available at: http://who-umc.org/ (accessed 17 October 2014).
25. Alten R. Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis, 2011;3:133–149.
26. Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence, 2013;7:653–666.
27. Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol, 1995;90:2134–2139.
28. Berglund L, Brunzell JD, Goldberg AC et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012;97:2969–2989.
29. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am, 1990;19:783–791.
30. Lindkvist B, Appelros S, Regner S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology, 2012;12:317–324.
31. Zhang H, Neuhofer P, Song L et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Investig, 2013;123:1019–1031.
32. Fattori E, Cappelletti M, Costa P et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med, 1994;180:1243–1250.
33. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol, 2014;26:2–12.